StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) company profile

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.40−0.05 (-10.74%)

Close on Nov 17, 2026Market cap $110.95MP/E –Yield –

About Akebia Therapeutics

Pharmaceutical Preparations, SIC 2834

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease and related conditions. Its primary commercial products are Vafseo (vadadustat), an oral hypoxia-inducible factor medicine for anemia associated with chronic kidney disease in adult dialysis patients, and Auryxia (ferric citrate), an oral treatment used for serum phosphorus control in dialysis-dependent chronic kidney disease and iron deficiency anemia in non-dialysis chronic kidney disease. The company's development pipeline includes mid-stage candidates such as praliciguat for focal segmental glomerulosclerosis and AKB-097 for complement-mediated kidney diseases, alongside early-stage programs exploring acute kidney injury, lung injury, and pediatric retinal disease. Its customers and target end-users encompass dialysis organizations, nephrologists, and adult patients undergoing kidney-related medical care.

The company operates commercially within the United States, maintaining contracts that provide prescribing access across dialysis clinic networks nationwide, and commercializes therapies internationally through regional partner collaborations across 37 countries where its lead product holds regulatory approval. The provided text contains no details regarding the location of its corporate headquarters.

Summary of the business section of Akebia Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Akebia Therapeutics, Inc.
Founded
2007
Headquarters
Waltham, MA
Address
180 Third Avenue, Floor 2 02451
Phone
(617) 871-2098
Employees
194, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
AKBA
Exchange
Nasdaq
IPO date
Mar 21, 2014
Shares outstanding
277M, Jul 31, 2026
Public float
$946.38M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1517022
CUSIP
00972D105
ISIN
US00972D1054
FIGI
BBG000R33R00
Share class FIGI
BBG001T922S9
LEI
549300CBQEHMKEEGNX42
EIN
20-8756903

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John P. ButlerCEO and President, Director3,878,492
Erik OstrowskiSVP, CFO, CBO & Treasurer616,616
Steven Keith BurkeSVP, Chief Medical Officer948,432
Nicholas GrundChief Commercial Officer561,750
Richard C. MalabreSVP, Chief Accounting Officer312,772
Carolyn M. RucciSVP, Chief Legal Officer588,378
Leanne M. ZumwaltDirector145,100
Cynthia SmithDirector196,633
Adrian AdamsDirector236,200
Michael W. RogersDirector197,429
Myles WolfDirector169,081
Ron FriesonDirector165,200
Philip J. VickersDirector–
Steven C. GilmanDirector152,830

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.65M$4.22M$1.79M$58$125
FY2024$4.26M$5.57M$1.43M$68$93
FY2023$2.78M$4.50M$1.23M$44$94
FY2022$3.07M$707.64K$1.37M$21$90
FY2021$3.13M$2.42M$1.40M$81$100
FY2020$5.93M$1.99M$1.90M$44$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
John P. Butler
President and Chief Executive Officer
$864.01K$2.16M$2.02M$580.97K$18.22K$5.65M+33%
Erik J. Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
$552.92K$436.58K$562.92K$223.07K$16.88K$1.79M+48%
Steven K. Burke, M.D.
Senior Vice President, Chief Research & Development and Medical Officer
$600.54K$436.58K$562.92K$242.29K$17.50K$1.86M+3%
Nicholas P. Grund
Senior Vice President, Chief Commercial Officer
$506.74K$436.58K$562.92K$204.67K$17.50K$1.73M-7%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 21, 2014
Offer price
$17.00
Securities offered
5,882,353
Gross proceeds
$100.00M
Exchange
Nasdaq
First trading day
Mar 20, 2014
First-day close
$26.70+57.0%
Lock-up ends (est.)
Sep 16, 2014

“Per share Total Initial public offering price $ 17.00 $ 100,000,001 Underwriting discounts and commissions(1) $ 1.19 $ 7,000,000 Proceeds, before expenses, to Akebia $ 15.81 $ 93,000,001 (1) See “Underwriting” for additional disclosure regarding underwriting discounts, commissions and expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 194 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?